{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276881","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.253316+00:00","generated_at":"2026-06-22T07:40:02.551348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cerus Q3 revenue up 10% to $46.3M; narrows FY product revenue guidance to $160-162M","bullets":["Net loss improved to $8.5M ($0.05/sh) from $12.4M ($0.07/sh) in Q3 2021.","Product gross margin expanded to 55.4% from 51.3% YoY; adjusted EBITDA loss narrowed to $2.7M.","Cash and investments at $103.8M; net cash used in ops $2.1M vs $6.6M prior year.","Guidance narrowed to $160-162M product revenue from $160-165M, citing FX headwinds.","Awarded $9.1M DoD contract for LyoCryo; Health Canada approved 7-day platelet shelf life."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276881","json":"https://secwatch.observer/filing/0001193125-22-276881.json","markdown":"https://secwatch.observer/filing/0001193125-22-276881.md","text":"https://secwatch.observer/filing/0001193125-22-276881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522276881/0001193125-22-276881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522276881/d306498d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:40:02.551348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b20ee8e73fe5d1e72af09d7dc800e1c90cda5ff2","claim":"CERUS CORP reported third quarter ended September 30, 2022 results: revenue $46.3 million, net income $8.5 million, EPS $0.05 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Cerus Corporation Announces Third Quarter Financial Results Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind CONCORD, CA, November 3, 2022 - Cerus Corporation","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522276881/0001193125-22-276881-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$46.3 million"},{"label":"Net income","value":"$8.5 million"},{"label":"EPS","value":"$0.05 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}